Drug development
The development of biotechnologically produced drugs has made it possible to treat diseases at their cause, to do this more efficiently and with fewer side effects, or even to cure diseases. This is the focus of five biotechnology companies on Campus Berlin-Buch.
The spectrum of their drug development includes highly specific cancer antibodies (Glycotope GmbH), novel treatments targeting the cause of heart failure (Berlin Cures GmbH) or atrial fibrillation (OMEICOS Therapeutics GmbH), extremely effective antibiotics (MerLion Pharmaceuticals) and RNAi-based therapeutics for systemic cancers that can selectively regulate disease-related genes (Silence Therapeutics). Here, T-Knife, a spin-off from the Charité and the Max Delbrück Center, is developing one of the first T cell receptor gene therapies in Germany.
News innovation
Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany
Eckert & Ziegler (ISIN DE0005659700, SDAX) congratulates Telix Pharmaceuticals Limited (Telix) on the approval of its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-6...
more ...Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum
Eckert & Ziegler successfully completes the 3rd annual Boston Radionuclide Theranostics Forum, underscoring its continued leadership in the radiopharmaceutical industry.
more ...Eckert & Ziegler Wins “Best Managed Companies Award” for the Second Time
Eckert & Ziegler SE (ISIN DE0005659700) has once again been honored with the “Best Managed Companies Award”. The award, presented by Deloitte Private, UBS, the Frankfurter Allgemeine Zeitung and the F...
more ...Events Campus
28.06.2025, 16:00
Lange Nacht der Wissenschaften 2025
Mitmach-Experimente, Shows, Laborführungen
more ...
